Fertility and Sterility Journal Recognizes Outstanding Scientific Paper Authored by RMA Fellow successful Collaboration with Juno Genetics
, /PRNewswire/ -- The apical diary successful the tract of reproductive medicine, Fertility and Sterility, has named Julia Kim, MD, victor of its 2022 Investigator Achievement Award. Dr. Kim is archetypal writer of a landmark survey connected preimplantation familial investigating for aneuploidy (PGT-A). The probe was conducted successful collaboration with Juno Genetics during her fellowship astatine Reproductive Medicine Associates (RMA), portion of the IVIRMA fertility network. The prestigious grant recognizes an exceptional insubstantial successful which the archetypal writer is little than 5 years retired of fellowship grooming oregon little than 35 years old. The grant was precocious presented to Dr. Kim astatine the American Society for Reproductive Medicine (ASRM) Scientific Congress successful Anaheim, California.
The study, "The concordance rates of an archetypal trophectoderm biopsy with the remainder of the embryo utilizing PGTSeq, a targeted next-generation sequencing level for preimplantation familial testing-aneuploidy," was Dr. Kim's thesis task and utilized Juno Genetics' PGTSeq assay. The results of 300 archetypal clinical-grade biopsies from blastocyst embryos were compared with those from consequent rebiopsies of those embryos. The survey assessed the reproducibility of the objective effect arsenic an indicator of trial accuracy. For some mean (euploid) and abnormal (aneuploid) results, astir 100% concordance was demonstrated. Conversely, erstwhile archetypal biopsy results were predicted to beryllium mosaic – successful which the fig of copies of a chromosome is betwixt mean and abnormal, a effect that causes uncertainty for clinicians and patients - rebiopsies showed mediocre reproducibility, with lone 2% of embryos showing afloat mosaicism. This information illustrates the debased predictive worth of an archetypal mosaic diagnosis and questions the objective inferior of mosaicism reporting, an important information for diligent care.
"It is an grant to person this grant from Fertility and Sterility," said Dr. Kim. "The probe for which I americium receiving the grant would not person been imaginable without the combined efforts of an unthinkable squad astatine IVIRMA and Juno Genetics. Our findings further endorse PGTSeq arsenic 1 of the astir validated PGT-A platforms successful embryo familial testing."
Dr. Marie Werner, a erstwhile RMA chap who was precocious appointed the caller manager of its fellowship program, added, "We are arrogant to observe and stock successful Fertility and Sterility's designation of Dr. Kim's ground-breaking enactment successful collaboration with Chaim Jalas and the Juno Genetics squad during her clip arsenic a chap astatine RMA."
PGT-A is performed connected thousands of IVF cycles successful the U.S. each twelvemonth and the process tests DNA from conscionable a fewer cells from the processing embryo. Because the results are utilized to marque objective decisions regarding which embryos are transferred and which are discarded, utilizing a trial that accurately predicts the objective result is cardinal to realizing the benefits of PGT-A. However, astir each PGT laboratory uses a customized trial assay and each laboratory is independently liable for demonstrating that their assay has been decently validated. Juno's PGTSeq is the lone PGT-A trial presently successful usage with published prospective, non-selection validation information supporting it. Juno's groundbreaking 2020 survey "A multi-center, prospective, blinded, non-selection survey evaluating the predictive worth of an aneuploid diagnosis with PGT-A and the interaction of biopsy," demonstrated a astir 100% affirmative predictive worth of the PGTSeq level successful diagnosing embryos that are not expected to pb to a palmy pregnancy, and was a finalist for the ASRM 2020 Prize Paper Award.
"Juno Genetics is honored to beryllium recognized by Fertility & Sterility for our technological contributions. We are mounting rigorous standards for PGT prime and validation and are committed to ongoing probe successful embryo diagnostics," stated Antonio Capalbo, PhD, Juno's caller Chief Genomics Officer. "Dr. Kim's insubstantial perfectly complements and builds upon Juno's different industry-leading publications connected PGT-A, providing further compelling grounds astir PGT-A accuracy erstwhile decently handled and validated successful preclinical and objective studies."
Chaim Jalas, the COO and Director of Technology Development astatine Juno and elder writer connected the study, added, "Completing due analytical and objective validations of individualized laboratory PGT-A assays anterior to objective usage is 1 of the astir captious and underrecognized components of liable usage of investigating successful IVF programs. Without diligent attraction paid to this step, the affirmative and antagonistic predictive values of the PGT-A results cannot beryllium accurately assessed. This accusation is captious for evidence-based counseling and diligent care."
Mosaic Research Presented astatine ASRM
At the 2022 ASRM conference, the RMA and Juno teams besides presented the largest blinded non-selection result information acceptable connected the transportation of putative mosaic embryos. Dr. Pavan Gill, existent RMA fellow, presented objective result information from astir 5000 embryos transferred with mosaic PGT-A findings masked. Embryos investigating antagonistic for full chromosome aneuploidy connected the PGTSeq assay, including those with mosaic findings, were classified arsenic being suitable for transfer; therefore, embryos were selected for usage without cognition of their imaginable mosaic status. Sustained gestation rates were not statistically antithetic betwixt embryos with and without putative mosaic findings, supporting the conception that mosaicism predicted by PGT investigating whitethorn beryllium a benign uncovering without known objective utility. The survey results suggest that by clinically reporting mosaic findings and thereby limiting the transportation of specified embryos, embryos with bully reproductive imaginable are being unnecessarily deprioritized oregon adjacent excluded from diligent use, a signifier that whitethorn bounds patients' chances for occurrence done IVF.
"Juno Genetics is the lone laboratory that has thoroughly and prospectively evaluated the objective value of each types of mosaic PGT-A findings. We are arrogant to beryllium an planetary person successful embryo diagnostics and reproductive genetics," said Jalas. Capalbo added, "we are besides arrogant that our probe and efforts volition lend to important advancements successful technological guidelines and recommendations from applicable societies successful the tract of reproductive medicine, yet improving attraction outcomes of infertile couples undergoing IVF."
About RMA
Reproductive Medicine Associates (RMA) has been helping physique families done the astir precocious attraction options and patient-centered fertility attraction for implicit 20 years. RMA is simply a person successful IVF research, pioneering the Single Embryo Transfer (SET), expanding information for ma and babe and Pre-Implantation Genetic Testing (PGT-A), dramatically expanding palmy outcomes. With entree to practices nationwide, RMA has helped invited implicit 50,000 babies into loving families. Learn much astatine rmanetwork.com.
About Juno Genetics
Our ngo is to supply grounds based, clinically utile accusation of the highest prime for patients who are undergoing fertility treatments. Juno genetics is dedicated to advancing cognition and enhancing outcomes successful embryonic research, diagnosis, and education. Learn much astatine www.junogenetics.com.
View archetypal contented to download multimedia:https://www.prnewswire.com/news-releases/groundbreaking-pgt-a-genetic-test-research-receives-prestigious-investigator-achievement-award-301667839.html
SOURCE Reproductive Medicine Associates